Experience
Freshworks Agrees to Acquire Device42
May 3, 2024
Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.Cooley advised Freshworks (Nasdaq: FRSH), a company that creates artificial intelligence-boosted business software for IT, customer support, sales, and marketing teams to make them more efficient and deliver more value for immediate business impact, on its agreement and plan of merger with D42 Parent (Device42), pursuant to which Freshworks – through its wholly owned subsidiary, Doppler Merger Sub –will acquire all of the outstanding equity interests of Device42 for an aggregate purchase price of approximately $230 million.
Related contacts
Related Practices & Industries
Rubrik Announces $752 Million Upsized IPO
April 29, 2024
Cooley advised Rubrik, the Zero Trust Data Security Company delivering data security and operational resilience for enterprises, on its $752 million initial public offering. Rubrik issued and sold 23,500,000 shares of Class A common stock priced at $32 per share, with a 30-day option for the underwriters to purchase up to 3,525,000 additional shares of Class A common stock.
Related contacts
Related Practices & Industries
Hootsuite to Acquire Talkwalker
April 8, 2024
Cooley advised Hootsuite, a global leader in social media management, on its definitive agreement to acquire Talkwalker, a top artificial intelligence-powered social listening solution.
Related contacts
Related Practices & Industries
Adaptive Phage Therapeutics Enters Into Definitive Merger Agreement With BiomX
March 6, 2024
Cooley advised Adaptive Phage Therapeutics, a US-based, privately held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections, on its definitive merger agreement with BiomX, a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria.
Related contacts
Alto Neuroscience Announces $147.9 Million IPO
February 6, 2024
Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.
Related contacts
Related Practices & Industries
Related news and events
Admissions & credentials
California
District of Columbia
New York
Rankings & accolades
Legal 500 US: US Taxes: Non-Contentious (2023)
Who’s Who Legal, Corporate Tax: Advisory (2022)
Washington DC Super Lawyers (2012 – 2015)